Compare TG Therapeutics Inc (TGTX) vs Financial Select Sector SPDR Fund (XLF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Financial Select Sector SPDR Fund — how do they compare? TG Therapeutics Inc trades at $55.37 (market cap $8.16B), while Financial Select Sector SPDR Fund trades at $54.73 (market cap $50.06B). The key difference: Financial Select Sector SPDR Fund is far larger — about 6.1× TG Therapeutics Inc's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Financial Select Sector SPDR Fund nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold TG Therapeutics Inc for 16 Days and Financial Select Sector SPDR Fund for 104 Days on average.
| TGTX | XLF | |
|---|---|---|
Market Cap | $8.16B | $50.06B |
Volume | 1,735,121 | 47,464,120 |
Sector | Health | — |
52-Week High | $59.06 | $58.55 |
52-Week Low | $26.94 | $47.80 |
Typical Hold Time | 16 Days | 104 Days |
Enterprise Value | $8.37B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $53.34, up 0.74% today, but faces bearish technical signals despite strong profitability metrics like a 55.22% net income margin. Recent earnings misses and a shareholder investigation create headwinds, though revenue growth and a high analyst buy consensus of 84.62% suggest underlying strength. The stock's current price is near key support at $52, with resistance at $54.
The outlook is mixed: robust revenue growth and institutional buying support upside toward the $80.50 consensus target, but earnings misses and legal risks pose challenges. Investors should weigh the company's MS therapy momentum against execution and regulatory uncertainties for balanced risk-reward assessment.
XLF trades at $54.23, up 0.89% on the day, while technical indicators show a bearish bias with moving averages signaling caution. The ETF faces sector headwinds as financial stocks lag the S&P 500 by the widest margin since 1990 despite rising bank profits. Recent Fed stress test changes and interest rate hikes create both opportunities and challenges for financial sector performance.
Financial sector exposure through XLF offers potential upside from rising interest rates, though regulatory uncertainty and market underperformance present near-term risks. The ETF's focus on large-cap financial firms provides stability, but sector rotation trends and political volatility could impact medium-term returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Financial Select Sector SPDR Fund
The fund generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: diversified financial services; insurance; banks; capital markets; mortgage real estate investment trusts; consumer finance; thrifts; and mortgage finance. The fund is non-diversified.
Read more on XLF →
